Haft Group - Counseling Small and Mid-Cap Ventures for 35 Years
Bringing Chinese Companies Public in the US Market
Welcome to the West! Emerging companies from China and elsewhere in Asia deserve the special attention available from The Haft Group and its associates in developing relations with New York investors, financial and professional service providers and making their mark with media.
The Haft Group and its seasoned associates are looking actively to spearhead investor relations and banking relationships with emerging corporate entities seeking exposure in US markets. Experienced with both US and Canadian securities, Haft's New York investor base and corporate contacts will be a "likely home" for China's growth companies seeking IR and banking requirements.
Peter Lau, a member of my advisory board has developed important relations with companies in China over the years. He is a seasoned investment banker raising a lot of capital for Chinese companies. Another member who has done significant business in China is Irving Bizar. Jay Miller, a securities counsel, and Edge Wang, our outside advisor, have also raised significant capital. We know the Chinese markets and we know why a Chinese company would want to come to the States. Whether the company we work with is in academia, in resources, or in shipping, our mission is the same - to create additional capital, create additional exposure, and additional M&A opportunities.
Dr. Edge Wang has extensive experience in biotechnology industry both in North America and China. For the last two years, he has been serving as venture partner/advisor for several firms such as Burrill and Company and Diamond Tech Venture.
Dr. Wang was the President and CEO and a member of the Board of Directors of WEX Pharmaceuticals Inc., a public Canadian Company headquartered in Vancouver with operations in Hong Kong and China. He took the company through its difficult time after the termination of clinical trials. With Dr. Wang’s leadership, the company re-established its clinical studies and raised more than $20M for its next steps in new drug development.